This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Mergers & Acquisitions

Jul. 29, 2015

Sullivan, Latham advise in Teva's $40.5 billion buyout offer of Activis

Consolidation volume in the pharmaceutical market broke financial records Monday after Teva Pharmaceuticals Industries Ltd. announced a $40.5 billion buyout offer of Allergan PLC's generic drugmaking branch Actavis PLC.


By Banks Albach


Daily Journal Staff Writer


Annual consolidation volume in the pharmaceutical market broke financial records Monday
after Teva Pharmaceuticals Industries Ltd. announced a $40.5 billion buyout offer
of Allergan PLC's generic drugmaking branch Actavis PLC, an effort aided by attorneys
from Sullivan & Cromwell LLP.


Latham & Watkins LL...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up